H3P47, H3 histone pseudogene 47, 115482706

N. diseases: 65; N. variants: 0
Disease: Hydatidiform Mole, Partial ×
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0334529
Disease: Hydatidiform Mole, Partial
Hydatidiform Mole, Partial 		0.100 Biomarker disease BEFREE Our data suggest that the use of p57 and Ki-67 IHC cannot reliably distinguish PM from NMAs. 30394942 2020
CUI: C0334529
Disease: Hydatidiform Mole, Partial
Hydatidiform Mole, Partial 		0.100 Biomarker disease BEFREE IHC with p57 was negative in 96 per cent CM and positive in 100 and 95 per cent PM and non-molar controls, respectively. 28574027 2017
CUI: C0334529
Disease: Hydatidiform Mole, Partial
Hydatidiform Mole, Partial 		0.100 Biomarker disease BEFREE Recent studies have demonstrated the value of ancillary techniques, including p57 immunohistochemistry and short tandem repeat genotyping, for distinguishing hydatidiform moles (HM) from nonmolar specimens and for subtyping HMs as complete hydatidiform moles (CHM) and partial hydatidiform moles (PHM). 23370656 2013
CUI: C0334529
Disease: Hydatidiform Mole, Partial
Hydatidiform Mole, Partial 		0.100 Biomarker disease BEFREE To our knowledge, this is the first description of a tetraploid PHM confirmed to be triandric by STR analysis, and the first description of p57 immunostaining in a confirmed triandric tetraploid PHM. 22123726 2012
CUI: C0334529
Disease: Hydatidiform Mole, Partial
Hydatidiform Mole, Partial 		0.100 Biomarker disease BEFREE Correct classification of all cases combined ranged from 51% to 75% by morphology and 70% to 80% with p57, with statistically significantly better performance of faculty only in round 2 (P-values of 0.69, <0.01, and 0.15 for rounds 1 to 3, respectively). p57 immunostaining significantly improved recognition of CHMs (P<0.01) and had high reproducibility (κ=0.93 to 0.96) but had no impact on distinction of PHMs and NMs. 22992698 2012
CUI: C0334529
Disease: Hydatidiform Mole, Partial
Hydatidiform Mole, Partial 		0.100 Biomarker disease BEFREE Even with morphologic assessment by gynecologic pathologists and p57 immunohistochemistry, 20% to 30% of cases will be misclassified, and, in particular, distinction of PHMs and NMs will remain problematic. 22245958 2012
CUI: C0334529
Disease: Hydatidiform Mole, Partial
Hydatidiform Mole, Partial 		0.100 AlteredExpression disease BEFREE Although p57 immunostaining alone can identify CHMs, which lack p57 expression because of the lack of maternal DNA, this analysis cannot distinguish PHMs from nonmolar specimens as both express p57 because of the presence of maternal DNA. 21293291 2011
CUI: C0334529
Disease: Hydatidiform Mole, Partial
Hydatidiform Mole, Partial 		0.100 AlteredExpression disease BEFREE We report a unique HM characterized by morphologic features suggesting an early CHM, including lack of p57 expression by immunohistochemistry, but with genetic features more in keeping with a PHM. 21881485 2011
CUI: C0334529
Disease: Hydatidiform Mole, Partial
Hydatidiform Mole, Partial 		0.100 Biomarker disease BEFREE In this study, a retrospectively collected set of morphologically typical CHMs (n = 8), PHMs (n = 10), and NMs (n = 12) was subjected to an analytic validation study of both short tandem repeat genotyping and p57 immunohistochemistry. 19815697 2009
CUI: C0334529
Disease: Hydatidiform Mole, Partial
Hydatidiform Mole, Partial 		0.100 AlteredExpression disease BEFREE Specimens with morphologic features suggestive of CHM yet retaining p57 expression should be subjected to molecular genotyping to establish a definitive diagnosis because misclassification as PHM underestimates the risk of persistent gestational trophoblastic disease. 19542869 2009